| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.79 [0.74, 0.84] | | < 1 | | 49% | 31 studies (31/-) | 100.0 % | some concern | critical | moderate | crucial | - |
| deaths (OS) (extension) | 0.69 [0.62, 0.77] | | < 1 | | 45% | 9 studies (9/-) | 100.0 % | some concern | serious | moderate | important | - |
| PFS (extension) | 0.64 [0.51, 0.79] | | < 1 | | 89% | 9 studies (9/-) | 100.0 % | some concern | serious | moderate | important | - |
| progression or deaths (PFS) | 0.74 [0.67, 0.81] | | < 1 | | 84% | 32 studies (32/-) | 100.0 % | some concern | critical | moderate | important | - |
| DOR | 2.27 [1.44, 3.57] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| objective responses (ORR) | 1.66 [1.43, 1.93] | | > 1 | | 76% | 31 studies (31/-) | 100.0 % | some concern | critical | moderate | non important | - |
| objective responses (ORR) (extension) | 1.94 [1.14, 3.31] | | > 1 | | 87% | 7 studies (7/-) | 99.3 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.72 [0.46, 1.12] | | < 1 | | 69% | 17 studies (17/-) | 92.8 % | some concern | critical | moderate | non important | - |
| AE (grade 3-4) | 0.77 [0.59, 1.02] | | < 1 | | 89% | 17 studies (17/-) | 96.7 % | some concern | low | moderate | non important | - |
| AE leading to death (grade 5) | 1.14 [0.89, 1.47] | | < 1 | | 32% | 16 studies (16/-) | 15.2 % | some concern | low | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.07 [0.78, 1.46] | | < 1 | | 86% | 15 studies (15/-) | 34.5 % | some concern | low | moderate | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 1.58 [1.08, 2.31] | | < 1 | | 56% | 5 studies (5/-) | 0.9 % | low | not evaluable | high | non important | - |
| SAE (any grade) | 1.46 [1.22, 1.75] | | < 1 | | 42% | 10 studies (10/-) | 0.0 % | some concern | low | moderate | non important | - |
| SAE (grade 3-4) | 0.34 [0.03, 3.42] | | < 1 | | 93% | 2 studies (2/-) | 81.8 % | some concern | not evaluable | moderate | non important | - |
| STRAE (any grade) | 1.05 [0.76, 1.46] | | < 1 | | 87% | 19 studies (19/-) | 38.3 % | some concern | low | moderate | non important | - |
| STRAE (grade 3-4) | 1.10 [0.70, 1.73] | | < 1 | | 87% | 11 studies (11/-) | 34.5 % | some concern | low | moderate | non important | - |
| TRAE (any grade) | 0.54 [0.37, 0.77] | | < 1 | | 92% | 23 studies (23/-) | 100.0 % | some concern | critical | moderate | non important | - |
| TRAE (grade 3-4) | 0.48 [0.32, 0.74] | | < 1 | | 96% | 24 studies (24/-) | 100.0 % | some concern | low | moderate | non important | - |
| TRAE leading to death (grade 5) | 0.95 [0.69, 1.31] | | < 1 | | 0% | 21 studies (21/-) | 61.9 % | some concern | low | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 0.95 [0.63, 1.42] | | < 1 | | 84% | 16 studies (16/-) | 60.5 % | some concern | low | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 1.58 [1.03, 2.44] | | < 1 | | 74% | 12 studies (12/-) | 1.9 % | some concern | low | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.49 [0.02, 14.75] | | < 1 | | 0% | 1 study (1/-) | 65.7 % | NA | not evaluable | | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 1.45 [0.34, 6.22] | | < 1 | | 0% | 6 studies (6/-) | 31.1 % | some concern | serious | moderate | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 2.05 [0.76, 5.52] | | < 1 | | 0% | 10 studies (10/-) | 7.7 % | some concern | low | moderate | non important | - |
| Alopecia TRAE (grade 3-4) | 0.56 [0.19, 1.65] | | < 1 | | 0% | 12 studies (12/-) | 85.3 % | some concern | critical | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.22 [0.12, 0.41] | | < 1 | | 87% | 19 studies (19/-) | 100.0 % | some concern | critical | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.77 [0.25, 2.39] | | < 1 | | 0% | 6 studies (6/-) | 67.1 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.46 [0.28, 0.75] | | < 1 | | 22% | 17 studies (17/-) | 99.9 % | some concern | low | moderate | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.86 [0.17, 4.48] | | < 1 | | 0% | 5 studies (5/-) | 57.0 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 3.38 [1.62, 7.04] | | < 1 | | 0% | 15 studies (15/-) | 0.1 % | some concern | low | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.62 [0.25, 1.53] | | < 1 | | 0% | 16 studies (16/-) | 85.0 % | some concern | critical | moderate | non important | - |
| Cough TRAE (grade 3-4) | 0.49 [0.01, 24.88] | | < 1 | | 0% | 1 study (1/-) | 63.6 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.83 [0.55, 1.26] | | < 1 | | 6% | 20 studies (20/-) | 80.7 % | some concern | critical | moderate | non important | - |
| Dermatitis acneiform TRAE (grade 3-4) | 0.50 [0.02, 15.30] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 1.50 [0.43, 5.29] | | < 1 | | 0% | 8 studies (8/-) | 26.4 % | some concern | serious | moderate | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.50 [1.01, 2.23] | | < 1 | | 10% | 22 studies (22/-) | 2.1 % | some concern | low | moderate | non important | - |
| Dizziness TRAE (grade 3-4) | 1.02 [0.06, 16.40] | | < 1 | | 0% | 2 studies (2/-) | 49.5 % | some concern | not evaluable | moderate | non important | - |
| Dysgeusia TRAE (grade 3-4) | 0.86 [0.15, 4.96] | | < 1 | | 0% | 5 studies (5/-) | 56.8 % | some concern | not evaluable | moderate | non important | - |
| Dyspepsia TRAE (grade 3-4) | 0.50 [0.02, 15.30] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
| Dyspnoea TRAE (grade 3-4) | 1.25 [0.25, 6.21] | | < 1 | | 0% | 3 studies (3/-) | 39.5 % | some concern | not evaluable | moderate | non important | - |
| Eczema TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 0.46 [0.01, 23.40] | | < 1 | | 0% | 1 study (1/-) | 64.7 % | NA | not evaluable | | non important | - |
| Epistaxis TRAE (grade 3-4) | 8.09 [0.43, 153.59] | | < 1 | | 0% | 1 study (1/-) | 8.4 % | NA | not evaluable | | non important | - |
| Erythema TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Fatigue TRAE (grade 3-4) | 0.71 [0.45, 1.11] | | < 1 | | 53% | 19 studies (19/-) | 93.3 % | some concern | low | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.40 [0.13, 1.21] | | < 1 | | 79% | 8 studies (8/-) | 94.7 % | some concern | serious | moderate | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 1.15 [0.37, 3.58] | | < 1 | | 0% | 2 studies (2/-) | 40.2 % | some concern | not evaluable | moderate | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Headache TRAE (grade 3-4) | 0.46 [0.02, 13.86] | | < 1 | | 0% | 1 study (1/-) | 66.9 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 4.40 [1.83, 10.61] | | < 1 | | 0% | 10 studies (10/-) | 0.0 % | some concern | low | moderate | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 1.39 [0.14, 13.49] | | < 1 | | 0% | 1 study (1/-) | 38.8 % | NA | not evaluable | | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 0.58 [0.10, 3.35] | | < 1 | | 0% | 4 studies (4/-) | 72.8 % | some concern | not evaluable | moderate | non important | - |
| Hypertension TRAE (grade 3-4) | 1.05 [0.61, 1.80] | | < 1 | | 0% | 3 studies (3/-) | 43.3 % | some concern | not evaluable | moderate | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.00 [0.39, 2.58] | | < 1 | | 0% | 16 studies (16/-) | 49.7 % | some concern | critical | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 1.79 [0.49, 6.61] | | < 1 | | 0% | 7 studies (7/-) | 19.1 % | some concern | serious | moderate | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.52 [0.68, 3.37] | | < 1 | | 0% | 20 studies (20/-) | 15.4 % | some concern | critical | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 1.62 [0.63, 4.14] | | < 1 | | 0% | 8 studies (8/-) | 15.8 % | some concern | not evaluable | moderate | non important | - |
| Increased ALT TRAE (grade 3-4) | 1.82 [0.97, 3.41] | | < 1 | | 0% | 11 studies (11/-) | 3.1 % | some concern | low | moderate | non important | - |
| Increased lacrimation (TRAE grade 3-4) | 0.99 [0.06, 15.95] | | < 1 | | 0% | 2 studies (2/-) | 50.3 % | some concern | not evaluable | moderate | non important | - |
| Increased lipase level TRAE (grade 3-4) | 5.04 [1.89, 13.47] | | < 1 | | 0% | 4 studies (4/-) | 0.1 % | some concern | not evaluable | moderate | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.90 [0.35, 2.35] | | < 1 | | 0% | 11 studies (11/-) | 58.2 % | some concern | low | moderate | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.18 [0.05, 0.59] | | < 1 | | 73% | 11 studies (11/-) | 99.8 % | some concern | critical | moderate | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 2.18 [0.55, 8.76] | | < 1 | | 0% | 5 studies (5/-) | 13.6 % | some concern | serious | moderate | non important | - |
| Mucosal inflammation TRAE (grade 3-4) | 0.23 [0.04, 1.21] | | < 1 | | 0% | 4 studies (4/-) | 95.8 % | some concern | not evaluable | moderate | non important | - |
| Myalgia TRAE (grade 3-4) | 1.04 [0.28, 3.83] | | < 1 | | 0% | 6 studies (6/-) | 47.7 % | some concern | not evaluable | moderate | non important | - |
| Myocarditis TRAE (grade 3-4) | 1.41 [0.11, 18.42] | | < 1 | | 0% | 2 studies (2/-) | 39.7 % | some concern | not evaluable | moderate | non important | - |
| Myositis TRAE (grade 3-4) | 0.95 [0.17, 5.22] | | < 1 | | 0% | 5 studies (5/-) | 52.1 % | some concern | serious | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 0.72 [0.43, 1.23] | | < 1 | | 26% | 19 studies (19/-) | 88.4 % | some concern | critical | moderate | non important | - |
| Nephritis TRAE (grade 3-4) | 1.82 [0.52, 6.35] | | < 1 | | 0% | 8 studies (8/-) | 17.5 % | some concern | serious | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.13 [0.07, 0.26] | | < 1 | | 87% | 19 studies (19/-) | 100.0 % | some concern | critical | moderate | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.63 [0.05, 8.17] | | < 1 | | 0% | 2 studies (2/-) | 63.9 % | some concern | not evaluable | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 2.19 [0.57, 8.43] | | < 1 | | 0% | 6 studies (6/-) | 12.8 % | some concern | serious | moderate | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.52 [0.02, 15.84] | | < 1 | | 0% | 1 study (1/-) | 64.4 % | NA | not evaluable | | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.74 [0.09, 6.34] | | < 1 | | 0% | 3 studies (3/-) | 60.8 % | some concern | not evaluable | moderate | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 0.77 [0.35, 1.68] | | < 1 | | 9% | 8 studies (8/-) | 74.4 % | some concern | not evaluable | moderate | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 0.59 [0.14, 2.50] | | < 1 | | 0% | 6 studies (6/-) | 76.2 % | some concern | serious | moderate | non important | - |
| Peripheral sensory neuropathy TRAE (grade 3-4) | 0.62 [0.05, 7.24] | | < 1 | | 57% | 3 studies (3/-) | 64.6 % | some concern | not evaluable | moderate | non important | - |
| Pneumonia TRAE (grade 3-4) | 0.54 [0.11, 2.64] | | < 1 | | 0% | 4 studies (4/-) | 77.6 % | some concern | not evaluable | moderate | non important | - |
| Pneumonitis TRAE (grade 3-4) | 2.02 [1.26, 3.22] | | < 1 | | 0% | 18 studies (18/-) | 0.2 % | some concern | critical | moderate | non important | - |
| Pruritic rash TRAE (grade 3-4) | 1.11 [0.09, 14.57] | | < 1 | | 0% | 2 studies (2/-) | 46.7 % | some concern | not evaluable | moderate | non important | - |
| Pruritus generalised TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 1.45 [0.56, 3.77] | | < 1 | | 0% | 14 studies (14/-) | 22.3 % | some concern | critical | moderate | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.60 [0.14, 2.64] | | < 1 | | 0% | 6 studies (6/-) | 75.1 % | some concern | serious | moderate | non important | - |
| Rash TRAE (grade 3-4) | 1.93 [1.09, 3.43] | | < 1 | | 0% | 20 studies (20/-) | 1.2 % | some concern | low | moderate | non important | - |
| Renal and urinary disorders TRAE (grade 3-4) | 1.06 [0.08, 13.83] | | < 1 | | 0% | 2 studies (2/-) | 48.3 % | some concern | not evaluable | moderate | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 8.91 [1.16, 68.41] | | < 1 | | 0% | 2 studies (2/-) | 1.8 % | some concern | not evaluable | moderate | non important | - |
| Sepsis TRAE (grade 3-4) | 0.91 [0.14, 6.07] | | < 1 | | 0% | 3 studies (3/-) | 54.0 % | some concern | not evaluable | moderate | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 2.45 [0.73, 8.21] | | < 1 | | 30% | 5 studies (5/-) | 7.3 % | some concern | not evaluable | moderate | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 4.10 [0.71, 23.60] | | < 1 | | 0% | 2 studies (2/-) | 5.8 % | some concern | not evaluable | moderate | non important | - |
| Skin exfoliation TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.76 [0.27, 2.14] | | < 1 | | 0% | 9 studies (9/-) | 69.7 % | some concern | not evaluable | moderate | non important | - |
